Catabasis names VP, development
This article was originally published in Scrip
Executive Summary
Catabasis Pharmaceuticals, which develops drugs for severe lipid disorders and rare diseases, has named Dr Angelika Fretzen vice-president of development. Prior to joining Catabasis Dr Fretzen was vice-president of pharmaceutical chemistry and development at Ironwood Pharmaceuticals. She has been responsible for discovery and development programs for small molecules and peptides in a variety of different disease areas and prior to joining Ironwood Dr Fretzen was an Alexander von Humboldt Fellow in the department of chemistry and chemical biology at Harvard University.